Scotiabank analyst Greg Harrison raised the firm’s price target on Liquidia (LQDA) to $34 from $30 and keeps an Outperform rating on the shares. Liquidia’s Q4 call reinforced the company’s commercial readiness ahead of Yutrepia’s approval in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the drug expected to be granted full approval in late Q2, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia price target lowered to $22 from $23 at BofA
- Liquidia Corporation Reports 2024 Financial Results
- Liquidia files to sell 1.12M shares of common stock for holders
- Liquidia Technologies: Promising Outlook with Yutrepia Launch and Legal Wins Support Buy Rating
- Buy Rating for Liquidia Technologies: Anticipated FDA Approval and Market Expansion Drive Positive Outlook